Table 2.
Incidences of prostate cancer and hazard ratios by rosiglitazone exposure.
| Rosiglitazone use | Cases followed |
Incident cases | Person-years | Incidence rate (per 100,000 person-years) |
Hazard ratio | 95% Confidence interval | P value | |
|---|---|---|---|---|---|---|---|---|
| Never users | 11495 | 84 | 48499.58 | 173.20 | 1.000 | |||
| Ever users | 11495 | 90 | 47977.54 | 187.59 | 1.089 | (0.808-1.466) | 0.5765 | |
| Cumulative dose (mg) | ||||||||
|---|---|---|---|---|---|---|---|---|
| Never users | 11495 | 84 | 48499.58 | 173.20 | 1.000 | |||
| <672 | 3757 | 26 | 15173.16 | 171.36 | 0.999 | (0.643-1.552) | 0.9961 | |
| 672-3584 | 3816 | 34 | 16964.46 | 200.42 | 1.147 | (0.770-1.709) | 0.4988 | |
| >3584 | 3922 | 30 | 15839.92 | 189.39 | 1.116 | (0.735-1.695) | 0.6063 | |